Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett’s esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC)

Table 1 Key questions

Key question	Question
1a	In adults (≥ 18 years) with chronic gastroesophageal reflux disease (GERD)^a with or without other risk factors^b, what is the effectiveness (benefits and harms) of screening for esophageal adenocarcinoma (EAC) and precancerous conditions (Barrett’s Esophagus (BE) and low- and high-grade dysplasia)? What are the effects in relevant subgroup populations?
1b	If there is evidence of effectiveness^c, what is the optimal time to initiate and to end screening, and what is the optimal screening interval (includes single and multiple tests and ongoing ‘surveillance’)?
2	In adults with chronic GERD with or without other risk factors,^b who have been offered, received, or allocated to receive screening for EAC and precancerous conditions (BE and low- and high-grade dysplasia), how do they weigh the benefits and harms of screening, and what factors contribute to these preferences and to their decisions to undergo screening?
3	What is the effectiveness (benefits and harms) of treatment for stage 1 EAC and precancerous conditions (BE and low- and high-grade dysplasia) in adults?

^aAs defined by study authors
^bRisk factors will be deemed so by included studies
^cIf there is evidence of at least moderate certainty of evidence of benefit, according to GRADE

ISSN: 2046-4053